Strategic partnerships Mebias Discovery seeks co-development or license partnerships for mu-opioid drug candidates, presenting a clear sales path to biotech and pharma companies looking to expand CNS, pain, and OUD portfolios.

Clinical-stage asset MEB-1170 has progressed to Phase I, signaling near-term collaboration potential for companies seeking early clinical-stage analgesics with reduced respiratory and abuse risk.

Specialized platform Leverage the unique GPCR platform with native purification and NMR to accelerate lead discovery and de-risk on-target side effects, offering a competitive edge to partners needing faster, cost-effective R&D.

Diverse funding signals Recent NIH support and multiple venture investors indicate validated interest and potential co-investment avenues that can be leveraged to structure co-development deals and milestone-based partnerships.

Market focus alignment Target CNS, Pain, OUD, Metabolic, and Inflammatory disorders aligns with high-need, high-value therapeutic areas, creating opportunities with larger pharma players seeking portfolio diversification and addiction/substance-use disorder solutions.